Many epidemiological studies have shown that the incidence of immune thrombocytopenia
(ITP) increases after age 60 years and peaks in patients over age 80 years. Therefore, ITP is …

Bruton tyrosine kinase (BTK) is expressed in B cells and innate immune cells, acting as an
essential signaling element in multiple immune cell pathways. Selective BTK inhibition has …

Introduction: Three distinct phases are recognized in immune thrombocytopenia (ITP): newly
diagnosed (≤ 3 months after diagnosis), persistent (> 3–12 months after diagnosis), and …

Immune thrombocytopenia (ITP) is the most common clinical bleeding disorder with a high
mortality rate and poor long-term survival quality in severe patients. There is controversy on …

Background: Immune thrombocytopenia (ITP) is an autoimmune disease resulting from
platelet destruction and impaired platelet production. Some patients experience relapses or …

Glucocorticoids (GC) are used as the first‐line treatment of immune thrombocytopenia (ITP),
but 10–20% of patients are insensitive to them. Regulatory T cells (Tregs) can maintain …

Background ITP is an immune-mediated disorder showing increased platelet destruction
and reduced platelet production. Glucocorticoids are the first-line treatment, but 10–20% of …

Cancer-induced thrombocytopenia (CIT) poses a significant clinical challenge, as it is
associated with increased morbidity and mortality in cancer patients. This review explores …

Cancer-induced thrombocytopenia (CIT) poses a significant clinical challenge, as it is
associated with increased morbidity and mortality in cancer patients. This review explores …

Purpose Recent studies suggested that adding other agents to corticosteroids as a first-line
treatment for immune thrombocytopenia (ITP) could improve outcomes. However …